Neos Therapeutics Inc (NASDAQ:NEOS) hit a new 52-week low during trading on Friday . The company traded as low as $5.10 and last traded at $5.20, with a volume of 10306 shares. The stock had previously closed at $5.40.
A number of equities research analysts have commented on NEOS shares. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 2nd. Wells Fargo & Co cut their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Neos Therapeutics in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $13.33.
The company has a debt-to-equity ratio of -2.36, a current ratio of 1.07 and a quick ratio of 0.84. The company has a market capitalization of $163.21 million, a price-to-earnings ratio of -1.94 and a beta of -0.31.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.08). Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. The firm had revenue of $11.36 million for the quarter, compared to analysts’ expectations of $11.90 million. sell-side analysts predict that Neos Therapeutics Inc will post -1.69 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of NEOS. Quantitative Systematic Strategies LLC purchased a new stake in shares of Neos Therapeutics during the 1st quarter worth about $123,000. Trexquant Investment LP bought a new position in shares of Neos Therapeutics in the 2nd quarter valued at approximately $131,000. Allianz Asset Management GmbH bought a new position in shares of Neos Therapeutics in the 1st quarter valued at approximately $161,000. New York State Common Retirement Fund raised its stake in shares of Neos Therapeutics by 38.5% in the 1st quarter. New York State Common Retirement Fund now owns 24,100 shares of the company’s stock valued at $200,000 after acquiring an additional 6,700 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Neos Therapeutics by 28.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock valued at $352,000 after acquiring an additional 12,500 shares in the last quarter. 47.47% of the stock is owned by institutional investors.
About Neos Therapeutics (NASDAQ:NEOS)
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Story: NASDAQ Stock Market Explained
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.